<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285751</url>
  </required_header>
  <id_info>
    <org_study_id>HTPR-ICU</org_study_id>
    <secondary_id>2012-002226-76</secondary_id>
    <nct_id>NCT02285751</nct_id>
  </id_info>
  <brief_title>High &quot;on Treatment&quot; Platelet Reactivity in the Intensive Care Unit</brief_title>
  <official_title>High &quot;on Treatment&quot; Platelet Reactivity in the Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High &quot;on treatment&quot; platelet reactivity is defined as a poor pharmacodynamic response to the
      administration of acetylsalicylic acid or clopidogrel. acetylsalicylic acid and clopidogrel
      are drugs commonly used to reduce platelet activity and prevent cardiovascular events. High
      &quot;on treatment&quot; platelet reactivity is associated with a higher cardiovascular event rate.

      Ticagrelor and prasugrel, like clopidogrel both P2Y12 inhibitors are effective in treating
      patients with High &quot;on treatment&quot; platelet reactivity to clopidogrel.

      Critically ill patients are a unique population with altered pharmacokinetic and
      pharmacodynamic properties. Gastrointestinal dysmotility with associated altered resorption
      and impaired microvascular function occur frequently in critically ill patients and may lead
      to altered resorption of orally administered drugs.

      The investigators will test a minimum of 100 patients treated with 100mg acetylsalicylic acid
      per os and 100 patients treated with 75mg clopidogrel per os to calculate the prevalence of
      high &quot;on treatment&quot; platelet reactivity.

      30 patients with high &quot;on treatment&quot; platelet reactivity to acetylsalicylic acid will be
      randomized to three new treatment groups. In the first group patients will receive 200mg
      acetylsalicylic acid per os, in the second group 100mg acetylsalicylic acid intravenously and
      in the third group 81mg chewable acetylsalicylic acid. Each group will contain 10 patients.
      Pharmacokinetics and pharmacodynamics will be reassessed to evaluate the new treatment.

      36 patients with high &quot;on treatment&quot; platelet reactivity to clopidogrel will be randomized to
      receive either an additional loading dose of 600mg clopidogrel (n=24) or to continue normal
      treatment as a control group (n=12). Pharmacokinetics and pharmacodynamics will be reassessed
      and those patients, who are tested again to have high &quot;on treatment&quot; platelet reactivity in
      spite of the additional loading dose, will now be randomized to receive either ticagrelor or
      prasugrel. The investigators expect about six patients per group. The twelve patients in the
      control group will continue normal treatment (75mg/day) until the end of the study.
      Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel will be assessed. Any
      patient, who is tested again with high &quot;on treatment&quot; platelet reactivity in spite of
      receiving prasugrel or ticagrelor, will be finally switched to the opposite drug and a final
      high &quot;on treatment&quot; platelet reactivity testing will be conducted.

      16 patients who are treated with 10mg prasugrel per os will be tested for HTPR and if
      positively tested will be switched to 2x90mg ticagrelor per os per day. Platelet reactivity
      will be reassessed to test whether switching the medication benefits the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacodynamics (Arachidonic acid induced aggregation test with multiplate electrode aggregometry)</measure>
    <time_frame>on average 3 days</time_frame>
    <description>Arachidonic acid induced aggregation test with multiplate electrode aggregometry of patients with high &quot;on treatment&quot; platelet reactivity to acetylsalicylic acid after receiving new treatments as explained.
adenosine diphosphate induced aggregation tested with multiplate electrode aggregometry of patients with high &quot;on treatment&quot; platelet reactivity to clopidogrel after an additional loading dose clopidogrel, or after receiving prasugrel or ticagrelor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of high &quot;on-treatment&quot; platelet reactivity in the intensive care unit</measure>
    <time_frame>maximum 2 weeks after admission</time_frame>
    <description>percentage of patients tested with high &quot;on treatment&quot; platelet reactivity according to defined values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetics (Serum levels of Salicylate/acetylsalicylic acid, clopidogrel-active metabolite, prasugrel-active metabolite, ticagrelor active-metabolite)</measure>
    <time_frame>on average 3 days</time_frame>
    <description>Serum levels of Salicylate/acetylsalicylic acid, clopidogrel-active metabolite, prasugrel-active metabolite, ticagrelor active-metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intensive care unit mortality</measure>
    <time_frame>maximum 90 days</time_frame>
    <description>discharge of ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of hemodynamically stable vs unstable ((defined by serum lactate&gt;2.1mmol/l, need for circulatory support)</measure>
    <time_frame>maximum 3 days</time_frame>
    <description>hemodynamically stable vs unstable (defined by serum lactate&gt;2.1mmol/l, need for circulatory support)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding (defined by TIMI-TRITON-38 criteria)</measure>
    <time_frame>average of 2 weeks within inclusion</time_frame>
    <description>assessment of major bleeding incidences defined by TIMI-TRITON-38 criteria</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>200mg acetylsalicylic acid per os</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with high &quot;on treatment&quot; platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg acetylsalicylic acid intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with high &quot;on treatment&quot; platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>81 mg chewable acetylsalicylic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with high &quot;on treatment&quot; platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75mg clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group for patients with high &quot;on treatment&quot; platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of prasugrel for patients who remain tested with high &quot;on treatment&quot; platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600mg clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>additional loading dose for 24 patients tested with high &quot;on treatment&quot; platelet reactivity to clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180mg ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of ticagrelor for patients who remain tested with high &quot;on treatment&quot; platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high &quot;on treatment&quot; platelet reactivity after being treated with 10mg prasugrel daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prasugrel 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treated with 10mg prasugrel daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <arm_group_label>200mg acetylsalicylic acid per os</arm_group_label>
    <arm_group_label>100mg acetylsalicylic acid intravenous</arm_group_label>
    <arm_group_label>81 mg chewable acetylsalicylic acid</arm_group_label>
    <other_name>100mg Thrombo-ASS</other_name>
    <other_name>200mg Thrombo-ASS</other_name>
    <other_name>81mg chewable aspirin</other_name>
    <other_name>100mg intravenous acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <arm_group_label>75mg clopidogrel</arm_group_label>
    <arm_group_label>600mg clopidogrel</arm_group_label>
    <other_name>75mg po clopidogrel</other_name>
    <other_name>600mg po clopidogrel (loading dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <arm_group_label>60mg prasugrel</arm_group_label>
    <arm_group_label>prasugrel 10mg</arm_group_label>
    <other_name>60mg prasugrel per os loading dose</other_name>
    <other_name>10mg prasugrel per os daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <arm_group_label>180mg ticagrelor</arm_group_label>
    <other_name>180mg ticagrelor per os (loading dose)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18years of age

          -  admittance to an intensive care unit

        Exclusion Criteria:

          -  recent surgery

          -  active bleeding

          -  known coagulation disorders

          -  discretion of the physician

          -  terminal illness (anticipated life expectancy &lt; 3months; e.g. due to cancer)

          -  pregnancy

          -  &lt;20000 platelets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Jilma, Ao. Univ.-Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Clinical Pharmacology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernd Jilma, Ao. Univ.-Prof. Dr. med.</last_name>
    <phone>0043140400</phone>
    <phone_ext>2981</phone_ext>
    <email>bernd.jilma@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Jilma, Ao. Univ.-Prof. Dr. med</last_name>
      <phone>0140400</phone>
      <phone_ext>2981</phone_ext>
      <email>bernd.jilma@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2012</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Bernd Jilma</investigator_full_name>
    <investigator_title>Ao. Univ.-Prof. Dr. Bernd Jilma</investigator_title>
  </responsible_party>
  <keyword>high on treatment platelet reactivity</keyword>
  <keyword>acetylsalicylic acid</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>critically ill</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

